Whats new

Whats new.

Maxim - Positive Updated Data for Efti + Keytruda in 1L H&N Cancer - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

December 12th 2024

For a copy of this analyst report please contact your Maxim advisor

Go back